Ribavirin for Hemorrhagic Fever With Renal Syndrome in Germany
Status:
Withdrawn
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This is a treatment protocol using IND Ribavirin-there is no control group. Hemorrhagic Fever
with Renal Syndrome (HFRS) is caused by a virus acquired by contact with chronically infected
rodent hosts. HFRS is present throughout Europe and caused mainly by Puumala and Dobrava
viruses. Treatment consists mainly of supportive care with careful attention to control of
blood pressure and fluid balance and/or dialysis. Early initiation of IND Intravenous
Ribavirin has been shown to be an effective treatment for HFRS and may prevent the need for
dialysis. It is important to initiate therapy based on a diagnosis consistent with HFRS
(determination if the disease is caused by Puumala or Dobrava virus is helpful) and a history
that makes exposure likely. This study will monitor the clinical events that occur with HFRS
as well as the safety and efficacy of Ribavirin.
Phase:
Phase 2
Details
Lead Sponsor:
U.S. Army Medical Research and Development Command U.S. Army Medical Research and Materiel Command